Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials

Clinical Therapeutics

Volumn 21, Issue 2, 1999, Pages 296-308

  Einarson, Thomas R ^a   Arikian, Steven R ^b,c   Casciano, Julian ^b   Doyle, John J ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Analytica Group   (United States)

Author keywords

Depression; Efficacy; Extended release venlafaxine; Meta analysis; Selective serotonin reuptake inhibitors; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; VENLAFAXINE XR;

CALCULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG CHOICE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032921491     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88287-9     Document Type: Article

References (69)

1. 1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
2. 2. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164:665-673.
3. 3. Morton WA, Sonne SC, Verga MA. Venlafaxine: A structurally unique and novel antidepressant. Ann Pharmacother. 1995;29:387-395.
4. 4. Asberg M, Eriksson B, Martensson B. Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry. 1986;47:23-35.
5. 5. Cole JO, Bodkin JA. Antidepressant drug side effects. J Clin Psychiatry. 1990;51:21-26.
6. 6. Ellingrod VL, Perry PJ. Venlafaxine: A heterocyclic antidepressant. Am J Hosp Pharm. 1994;51:3033-3046.
7. 7. Einarson TR, Arikian SR, Swceney S, Doyle J. A model to evaluate the cost effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther. 1995;17:136-153.
8. 8. Entsuah R, Chitra R. A benefit-risk analysis of once daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull. 1997;33:671-676.
9. 9. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association; 1987.
10. 10. Montgomery SA, Asberg M. A new depression scale designed to be more sensitive to change. Br J Psychiatry. 1979;43:382-389.
11. 11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
12. 12. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups: Antifungal onychomycosis lacquers as example. Clin Ther. 1997;19:559-569.
13. 13. Rosenthal R. Meta-Analysis in the Social Sciences, Beverly Hills, Calif: Sage Publications; 1984.
14. 14. Koran LM, Hamilton SH, Hertzman M, et al. Predicting response to fluoxetine in geriatric patients. J Clin Psychopharmacol. 1995;15:421-427.
15. 15. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. Acta Psychiatr Scand. 1989;80:125-129.
16. 16. Fawcett J, Zajecka JM, Kravitz HM, et al. Fluoxetine versus amitriptyline in adult outpatients with major depression. Curr Ther Res. 1989;45:821-832.
17. 17. Altamura AC, Montgomery SA, Wemicke JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression, Br J Psychiatry. 1988;153:109-112.
18. 18. Taylor L. A double blind placebo controlled study of venlafaxine and venlafaxine-ER in outpatients with major depression. Protocol #0600B-208-US. Philadelphia, Pa: Wyeth-Ayerst Inc.; 1996.
19. 19. Smith J, Grant P. Double blind placebo controlled study of venlafaxine ER in outpatients with major depression. Protocol #0600B-209-US. Philadelphia, Pa: Wyeth-Ayerst Inc.; 1996.
20. 20. Protocol #211. Philadelphia, Pa: Wyeth-Ayerst Inc.; 1996.
21. 21. Protocol #360. Philadelphia, Pa: Wyeth-Ayerst Inc.; 1996.
22. 22. Hackett D. A randomized double blind placebo controlled fixed dose study of the efficacy and safety of venlafaxine extended release and paroxetine in depressed outpatients. Protocol #0600B-367EU. Paris: Wyeth-Ayerst France; 1996.
23. 23. Bremner JD. Fluoxetine in depressed patients: A comparison with imipramine. J Clin Psychiatry. 1984;45:414-419.
24. 24. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia, Int Clin Psychopharmacol. 1994;9:139-143.
25. 25. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry. 1985;46:26-31.
26. 26. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1996;20:57-71.
27. 27. Dominguez RA, Goldstein BJ, Jacobson AF, Steinbook RM. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry. 1985;46:84-87.
28. 28. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217-222.
29. 29. Dunbar GC, Claghom JL, Kiev A, et al. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand. 1993;87:302-305.
30. 30. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985;46:369-372.
31. 31. Feighner JP, Gardner EA, Johnston JA. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry. 1991;52:329-335.
32. 32. Geretsegger C, Stuppaeck CH, Mair M, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology. 1995;119:277-281.
33. 33. Haffmans PMJ, Timmerman L, Hoogduin CAL. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: A double-blind, multicentre study. Int Clin Psychopharmacol. 1996;11:157-164.
34. 34. Lapierre YD, Browne M, Horn E, et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry. 1987;48:65-68.
35. 35. Lydiard RB, Laird LK, Morton WA, et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: Effects on depression. Psychopharmacol Bull. 1989;25:68-70.
36. 36. Moon C, Vince M. Treatment of major depression in general practice: A double-blind comparison of paroxetine and lofepramine. Br J Clin Pharmacol. 1996;50:240-244.
37. 37. Muijen M, Roy D, Silverstone T. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand. 1988;78:384-390.
38. 38. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol. 1996;11:129-136.
39. 39. Rickels K, Amsterdam JD. Avallone MF. Fluoxetine in major depression: A controlled study. Curr Ther Res Clin Exp. 1986;39:559-563.
40. 40. Rosenberg C, Damsbo N, Fuglum E, et al. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol. 1994;9(Suppl 1):41-48.
41. 41. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine versus imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985;46:53-58.
42. 42. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164-168.
43. 43. Ansseau M, Devoitille J, Papart P, et al. Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. J Clin Psychopharmacol. 1991;11:160-165.
44. 44. Ansseau M, Von Frenckell R, Mertens C. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology. 1989;98:163-168.
45. 45. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res. 1996;30:441-451.
46. 46. Brunswick DJ, Amsterdam JD, Potter L, et al. Relationship between tricyclic antidepressant plasma levels and clinical response in patients treated with desipramine or doxepin. Acta Psychiatr Scand. 1983;67:371-377.
47. 47. DelZompo M, Bernardi R, Burrai C, Bocchetta A. A double-blind study of minaprine versus amitriptyline in major depression. Neuropsychobiology. 1990;24:79-83.
48. 48. Eriksson B, Nagy A, Starmark J, Thelander U. Alprazolam compared to amitriptyline in the treatment of major depression. Acta Psychiatr Scand. 1987;75:656-663.
49. 49. Feighner JP. Trazodone, a triazolopyridine derivative, in primary depressive disorder. J Clin Psychiatry. 1980;41:250-255.
50. 50. Gershon S, Mann J, Newton R, Gunther BJ. Evaluation of trazodone in the treatment of endogenous depression: Results of a multi-center double-blind study. J Clin Psychopharmacol. 1981;1:S39-S44.
51. 51. Kellams JJ, Klapper MH, Small JG. Trazodone, a new antidepressant: Efficacy and safety in endogenous depression. J Clin Psychiatry. 1979;40:390-395.
52. 52. Lecrubier Y, Moon CAI, Schifano F, et al. Efficacy of venlalaxine in depressive illness in general practice. Acta Psychiatr Scand. 1997;95:485-493.
53. 53. Mann JJ, Georgotas A, Newton R, Gershon S. A controlled study of trazodone, imipramine and placebo in outpatients with endogenous depression. J Clin Psychopharmacol. 1981;1:75-80.
54. 54. Mendels J, Schless AP. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry. 1986;47:357-361.
55. 55. O'Connor M, Grigor J. Double blind study comparing the efficacy of zimelidine and amitriptyline in endogenous depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 1984;8:127-132.
56. 56. Rickels K, Chung HR, Csanalosi IB. Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry. 1987;44:862-866.
57. 57. Schweizer E, Feighner J, Mandos LA. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychopharmacol. 1994;55:104-108.
58. 58. Syvalahti E, Salminen J, Lehtinen V. A double-blind comparison of zimelidine and amitriptyline in depressive out-patients. J Int Med Res. 1982;10:250-256.
59. 59. Byerley WF, Reimherr FW, Wood DR, et al. Fluoxetine, a selective serotonin reuptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol. 1988;8:112-115.
60. 60. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4:313-322.
61. 61. Dunbar GC, Cohn JC, Fahre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br J Psychiatry. 1991;159:394-398.
62. 62. Fabre L, Birkhimer LJ, Zaborny BA, et al. Fluvoxamine versus imipramine and placebo: A double-blind comparison in depressed patients. Int Clin Psychopharmacol. 1996;11:119-127.
63. 63. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. J Clin Psychiatry. 1992;53:44-47.
64. 64. Itil TM, Shrivastava RK, Mukherjee S, et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in outpatients with primary depression. Br Clin Pharmacol. 1983;15(Suppl 3):433S-438S.
65. 65. March JS, Kobak KA, Jefferson JW, et al. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry. 1990;51:200-202.
66. 66. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry. 1990;51:18-27.
67. 67. Wagner W, Wakelin JS, Coleman BS, et al. Therapeutische Ergebnissen mit Fluvoxamine und der Einfluss Psychotroper Begleitmedikation auf Wirksamskeit und Vertragichkeit. Adv Pharmacother. 1985;1:33-65.
68. 68. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56:519-525.
69. 69. Einarson TR, Addis A, Mittmann N, Iskedjian M. Meta-analysis of venlatanine, SSRIs, and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol. 1998;5:205-216.